Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1985 Sep;82(18):6291–6294. doi: 10.1073/pnas.82.18.6291

The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.

D R Illingworth, D Corbin
PMCID: PMC391039  PMID: 2994068

Abstract

The biosynthesis of adrenal corticosteroids in humans depends on a continuous supply of cholesterol, which can be derived from both local synthesis and receptor-mediated uptake of low density lipoproteins (LDL) from plasma. Mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase [mevalonate:NAD+ oxidoreductase (CoA-acylating), EC 1.1.1.88] is an effective hypolipidemic agent in patients with heterozygous familial hypercholesterolemia. To determine whether mevinolin influences the adrenal production of corticosteroids, the adrenocortical response to a continuous 36-hr infusion of corticotropin (ACTH) was examined in eight patients with heterozygous familial hypercholesterolemia before, and again during, treatment with mevinolin (40-80 mg/day). The drug produced an average decrease of 28% and 34% in the plasma concentrations of total and LDL cholesterol. Serum cortisol levels showed similar increases in response to ACTH stimulation before and during mevinolin treatment, and the rates of excretion of urine-free cortisol were also similar. We conclude that clinically effective doses of mevinolin do not affect corticosteroid production by the adrenal cortex during prolonged ACTH stimulation in patients with heterozygous familial hypercholesterolemia.

Full text

PDF
6291

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AVIGAN J., STEINBERG D., VROMAN H. E., THOMPSON M. J., MOSETTIG E. Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. J Biol Chem. 1960 Nov;235:3123–3126. [PubMed] [Google Scholar]
  2. Alberts A. W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957–3961. doi: 10.1073/pnas.77.7.3957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bilheimer D. W., Grundy S. M., Brown M. S., Goldstein J. L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4124–4128. doi: 10.1073/pnas.80.13.4124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Borkowski A., Delcroix C., Levin S. Metabolism of adrenal cholesterol in man. I. In vivo studies. J Clin Invest. 1972 Jul;51(7):1664–1678. doi: 10.1172/JCI106968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown M. S., Kovanen P. T., Goldstein J. L. Receptor-mediated uptake of lipoprotein-cholesterol and its utilization for steroid synthesis in the adrenal cortex. Recent Prog Horm Res. 1979;35:215–257. doi: 10.1016/b978-0-12-571135-7.50009-6. [DOI] [PubMed] [Google Scholar]
  6. Carr B. R., Simpson E. R. Lipoprotein utilization and cholesterol synthesis by the human fetal adrenal gland. Endocr Rev. 1981 Summer;2(3):306–326. doi: 10.1210/edrv-2-3-306. [DOI] [PubMed] [Google Scholar]
  7. FORD R. V. The effect of MER-29, a cholesterol synthesis inhibitor, on adrenal function, blood clotting mechanisms, and serum lipids, before and after simulated stress in man. Prog Cardiovasc Dis. 1960 May;2:548–552. doi: 10.1016/s0033-0620(60)80030-8. [DOI] [PubMed] [Google Scholar]
  8. Grundy S. M., Bilheimer D. W. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance. Proc Natl Acad Sci U S A. 1984 Apr;81(8):2538–2542. doi: 10.1073/pnas.81.8.2538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gwynne J. T., Strauss J. F., 3rd The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands. Endocr Rev. 1982 Summer;3(3):299–329. doi: 10.1210/edrv-3-3-299. [DOI] [PubMed] [Google Scholar]
  10. Illingworth D. R., Alam N. A., Lindsey S. Adrenocortical response to adrenocorticotropin in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab. 1984 Jan;58(1):206–211. doi: 10.1210/jcem-58-1-206. [DOI] [PubMed] [Google Scholar]
  11. Illingworth D. R., Kenny T. A., Connor W. E., Orwoll E. S. Corticosteroid production in abetalipoproteinemia: evidence for an impaired response ACTH. J Lab Clin Med. 1982 Jul;100(1):115–126. [PubMed] [Google Scholar]
  12. Illingworth D. R., Kenny T. A., Orwoll E. S. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab. 1982 Jan;54(1):27–33. doi: 10.1210/jcem-54-1-27. [DOI] [PubMed] [Google Scholar]
  13. Illingworth D. R., Lees A. M., Lees R. S. Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism. 1983 Nov;32(11):1045–1052. doi: 10.1016/0026-0495(83)90075-6. [DOI] [PubMed] [Google Scholar]
  14. Illingworth D. R. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern Med. 1984 Nov;101(5):598–604. doi: 10.7326/0003-4819-101-5-598. [DOI] [PubMed] [Google Scholar]
  15. Illingworth D. R., Sexton G. J. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest. 1984 Dec;74(6):1972–1978. doi: 10.1172/JCI111618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kovanen P. T., Bilheimer D. W., Goldstein J. L., Jaramillo J. J., Brown M. S. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci U S A. 1981 Feb;78(2):1194–1198. doi: 10.1073/pnas.78.2.1194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mabuchi H., Haba T., Tatami R., Miyamoto S., Sakai Y., Wakasugi T., Watanabe A., Koizumi J., Takeda R. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med. 1981 Aug 27;305(9):478–482. doi: 10.1056/NEJM198108273050902. [DOI] [PubMed] [Google Scholar]
  18. Mabuchi H., Sakai T., Sakai Y., Yoshimura A., Watanabe A., Wakasugi T., Koizumi J., Takeda R. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med. 1983 Mar 17;308(11):609–613. doi: 10.1056/NEJM198303173081101. [DOI] [PubMed] [Google Scholar]
  19. NEY R. L., SHIMIZU N., NICHOLSON W. E., ISLAND D. P., LIDDLE G. W. CORRELATION OF PLASMA ACTH CONCENTRATION WITH ADRENOCORTICAL RESPONSE IN NORMAL HUMAN SUBJECTS, SURGICAL PATIENTS, AND PATIENTS WITH CUSHING'S DISEASE. J Clin Invest. 1963 Nov;42:1669–1677. doi: 10.1172/JCI104853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ohashi M., Carr B. R., Simpson E. R. Effects of adrenocorticotropic hormone on low density lipoprotein receptors of human fetal adrenal tissue. Endocrinology. 1981 Apr;108(4):1237–1242. doi: 10.1210/endo-108-4-1237. [DOI] [PubMed] [Google Scholar]
  21. RENOLD A. E., JENKINS D., FORSHAM P. H., THORN G. W. The use of intravenous ACTH: a study in quantitative adrenocortical stimulation. J Clin Endocrinol Metab. 1952 Jul;12(7):763–797. doi: 10.1210/jcem-12-7-763. [DOI] [PubMed] [Google Scholar]
  22. Rose L. I., Williams G. H., Jagger P. I., Lauler D. P. The 48-hour adrenocorticotrophin infusion test for adrenocortical insufficiency. Ann Intern Med. 1970 Jul;73(1):49–54. doi: 10.7326/0003-4819-73-1-49. [DOI] [PubMed] [Google Scholar]
  23. Tobert J. A., Bell G. D., Birtwell J., James I., Kukovetz W. R., Pryor J. S., Buntinx A., Holmes I. B., Chao Y. S., Bolognese J. A. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. J Clin Invest. 1982 Apr;69(4):913–919. doi: 10.1172/JCI110530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Yamaguchi K., Nakamura N., Uzawa H. Blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia. J Clin Endocrinol Metab. 1984 May;58(5):786–789. doi: 10.1210/jcem-58-5-786. [DOI] [PubMed] [Google Scholar]
  25. Yamamoto A., Sudo H., Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980 Mar;35(3):259–266. doi: 10.1016/0021-9150(80)90124-0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES